The HPRT1 Knockout Jurkat Polyclonal Cells product consists of a polyclonal population of Jurkat cells engineered by CRISPR/Cas9-mediated disruption of the HPRT1 gene locus, generating a heterogeneous HPRT1 loss-of-function model. This polyclonal knockout cell pool provides a biologically relevant system for studying purine salvage deficiency without clonal selection biases.
The host Jurkat cell line is an immortalized CD4+ T lymphocyte line established from an acute T-cell leukemia patient. Widely used in T-cell signaling, apoptosis, and metabolism research, Jurkat cells retain critical lymphoid traits, making them suitable for examining nucleotide metabolism in a physiologically relevant T-cell context.
HPRT1 encodes hypoxanthine-guanine phosphoribosyltransferase, which catalyzes the conversion of hypoxanthine to IMP and guanine to GMP using PRPP as a co-substrate. These reactions are central to the purine salvage pathway, replenishing purine nucleotide pools. HPRT1 activity is regulated by substrate availability (hypoxanthine and guanine) and PRPP levels. Downstream, IMP and GMP serve as precursors for ATP and GTP, respectively, connecting HPRT1 to energy metabolism and nucleic acid synthesis. Representative pathway components include salvage enzymes APRT, ADA, PNP, and de novo purine biosynthetic enzymes.
Disruption of HPRT1 in Jurkat cells impairs salvage of hypoxanthine and guanine, driving dependence on de novo purine synthesis and altering nucleotide pools. This metabolic shift recapitulates the biochemical defect in Lesch-Nyhan syndrome and Kelley-Seegmiller syndrome, disorders characterized by hyperuricemia and neurological dysfunction. Additionally, HPRT1-negative cells are resistant to 6-thioguanine, enabling studies of drug resistance and purine analog pharmacology in a T-cell model.
These polyclonal knockout cells support diverse applications, including 6-thioguanine cytotoxicity assays for functional validation, HPRT enzymatic activity assays, and Western blotting for protein-level confirmation. Metabolic profiling by LC-MS or HPLC quantifies purine nucleotide changes, while RT-qPCR assesses transcript reduction. The model is suited for Lesch-Nyhan disease modeling, hyperuricemia studies, and T-cell metabolic research exploring activation-induced nucleotide demands. For additional details, contact Ascent Research.
